Logo Medical Science Monitor

Call: +1.631.470.9640
Closed: National Holiday

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 January 2001

Primary hepatic carcinoid tumor: case report and review of 53 cases.

Masataka Iwao, Makoto Nakamuta, Munechika Enjoji, Hiroaki Kubo, Takayoshi Fukutomi, Yuichi Tanabe, Hidehiro Nishi, Ken-ichi Taguchi, Kazuhiro Kotoh, Hajime Nawata

Med Sci Monit 2001; 7(4): CS746-750 :: ID: 421075

Abstract

BACKGROUND: Primary hepatic carcinoid tumor (PHCT) is a extremely rare.The authors describe a patient with PHCT and review previously published cases of the disease.
CASE REPORT:A 75-year-old man, presenting with weight loss and pain in the right upper abdomen, had multiple massesin both lobes of the liver. He was diagnosed as PHCT by radiological examination, laboratory findingswith high levels of 5-hydroxyindoleacetic acid (5-HIAA) in the serum and urine, and histological findingsincluding positive staining of tumor cells for Grimelius and chromogranin A. The patient received totallytranscatheter arterial chemoembolization (TACE) five times over 27 months; this treatment provided excellentpalliation and caused a decrease in urinary 5-HIAA levels. Fifty-three cases of PHCT have been reportedin the English-language literature.
RESULTS: Analysis of these published cases revealed that PHCT occursin the middle age (mean age = 48.2 years) and is more frequent in females (males/females = 20/33 cases).Of the symptomatic patients, the major findings is abdominal pain, fullness, and/or a palpable mass (56%of symptomatic patients). In contrast, only 2 cases out of 53 presented with symptoms of typical carcinoidsyndrome. In most cases, PHCT was detected as a hypervascular lesion by radiological examination. Byhistological analysis, 80% and 84% of the cases were positive for Grimelius silver stain and immunohistochemicallypositive for chromogranin A, respectively. Surgical resection is the treatment primarily recommendedwith an 18% of recurrence rate and a 74% of a survival rate after 5 years. For unresectable and recurrentcases, TACE may be recommended.

Keywords: Primary hepatic carcinoid tumor

Add Comment 0 Comments

Editorial

01 October 2024 : Editorial  

Editorial: Potentials and Pitfalls in Targeting Glucagon-Like Peptide-1 (GLP-1) in the Management of Increasing Levels of Obesity

Dinah V. Parums

DOI: 10.12659/MSM.946675

Med Sci Monit 2024; 30:e946675

0:00

In Press

Clinical Research  

Evaluation of Neuromuscular Blockade: A Comparative Study of TOF-Cuff® on the Lower Leg and TOF-Scan® on th...

Med Sci Monit In Press; DOI: 10.12659/MSM.945227  

Clinical Research  

Acupuncture Enhances Quality of Life and Disease Control in Chronic Spontaneous Urticaria Patients on Omali...

Med Sci Monit In Press; DOI:  

Review article  

Sex and Population Variations in Nasopalatine Canal Dimensions: A CBCT-Based Systematic Review

Med Sci Monit In Press; DOI:  

Clinical Research  

Cold Pressor Test Induces Significant Changes in Internal Jugular Vein Flow Dynamics in Healthy Young Adults

Med Sci Monit In Press; DOI: 10.12659/MSM.946055  

Most Viewed Current Articles

17 Jan 2024 : Review article   6,057,747

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

14 Dec 2022 : Clinical Research   1,850,872

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

16 May 2023 : Clinical Research   694,012

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

07 Jan 2022 : Meta-Analysis   258,273

Efficacy and Safety of Light Therapy as a Home Treatment for Motor and Non-Motor Symptoms of Parkinson Dise...

DOI :10.12659/MSM.935074

Med Sci Monit 2022; 28:e935074

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750